Navigation Links
PTC Therapeutics' Antibacterial Program Receives $5 Million Award from the Wellcome Trust
Date:12/22/2011

SOUTH PLAINFIELD, N.J., Dec. 22, 2011 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the receipt of a $5 million Seeding Drug Discovery (SDD) Award from the Wellcome Trust to support the development of small-molecule drugs that target life-threatening infections caused by multidrug-resistant (MDR) Gram-negative bacteria.  PTC previously received a $5.4 million SDD Award from the Wellcome Trust to support its BMI1 oncology program.

(Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO)

The discovery and development of new and novel antibiotics are urgently needed due to the increased frequency of bacterial resistance to marketed antibiotics in the hospital and community settings.  Hospital-acquired infections present a major threat to patient health and quality of life.  The Centers for Disease Control and Prevention estimates that approximately 1.7 million hospital-acquired bacterial infections cause or contribute to nearly 100,000 deaths in the United States each year with similar data reported from Europe.  Gram-negative bacteria are responsible for more than 30 percent of these infections.  The major concern with MDR Gram-negative bacteria is there are limited options to effectively treat them.

"We are honored to expand our relationship with the Wellcome Trust through this second award," stated Stuart W. Peltz, Ph.D., President and Chief Executive Officer at PTC Therapeutics.  "This funding will support our ongoing efforts to develop novel antibiotics to treat infections caused by multidrug-resistant Gram-negative bacteria."

PTC has identified a novel structural class of molecules that have potent activity against Gram-negative bacteria that are resistant to marketed antibiotics.  The anti-infective program at PTC is currently in lead optimization and advancing towards identifying a Development Candidate.

About Wellcome Trust

The Wellcome Trust is a global charity dedicated to achieving extraordinary improvements in human and animal health.  It supports the brightest minds in biomedical research and the medical humanities.  The Trust's breadth of support includes public engagement, education and the application of research to improve health.  It is independent of both political and commercial interests. www.wellcome.ac.uk

About PTC Therapeutics, Inc.

PTC is a biopharmaceutical company that applies its expertise in RNA biology and drug development to pioneer novel oral treatments for patients living with serious and life-threatening conditions.  PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders, oncology, and infectious diseases.  PTC has developed proprietary technologies that it applies in its drug discovery activities and that have served as the basis for collaborations with leading biopharmaceutical companies such as AstraZeneca, Celgene, Genzyme, Merck, Pfizer and Roche. For more information, visit the company's website at www.ptcbio.com.


'/>"/>
SOURCE PTC Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Arecor Forms Collaboration With Lilly to Develop Advanced Formulations of Protein Therapeutics
2. Cerevast Therapeutics Receives CE Mark for Clotbust ER™ Ultrasound Stroke Treatment Device
3. Orexigen® Therapeutics Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock
4. Regulus Therapeutics Initiates an Orphan and Rare Disease microRNA Therapeutic Effort in Brain Cancer
5. Cell Therapeutics, Inc. Announces Institutional Investors Purchase $20 Million of Preferred Stock and Warrants
6. Pearl Therapeutics Reports Positive Phase 2b Results of PT001 in Patients With COPD
7. Echo Therapeutics to Present at the Oppenheimer Healthcare Conference
8. Pepscan Therapeutics Presents Protein Mimicry Platform for the Discovery of anti-GPCR Antibodies at International Antibody Conference
9. ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20)
10. Echo Therapeutics Announces Pricing of $5.4 Million Registered Direct Equity Financing
11. FDA Sets April 24, 2012 as PDUFA Goal Date for Cell Therapeutics Resubmitted Pixantrone New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...   Bay Area Lyme Foundation , collaborating ... for Tick Borne Illness , Harvard Medical School ... Medicine, University of California, Berkeley, and the Veterans ... finalists of Lyme Innovation , the first ... scientists, clinicians, researchers, entrepreneurs, and investors from several ...
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is ... a fitness app. The fitness app plans to fix the two major problems leading the ... one size fits all type program , They don’t eliminate all the reasons ...
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... To deal with these feelings, many turn to unhealthy avenues, such as drug or ... Center of Marne, Michigan, has released tools for healthy coping following a traumatic event. ...
Breaking Medicine News(10 mins):